StockData
CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW

Cardio Diagnostics Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.64−0.05 (-2.96%)

Close on Oct 19, 2026

Market cap
$4.85M
P/E (TTM)
–
Dividend yield
–

About Cardio Diagnostics

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Cardio Diagnostics Holdings, Inc. develops and commercializes artificial intelligence-driven, epigenetics-based clinical blood tests and platforms for cardiovascular disease. The company's core product offerings include Epi+Gen CHD, a test designed to assess the three-year risk of symptomatic coronary heart disease events, and PrecisionCHD, a test used to detect coronary heart disease alongside actionable clinical intelligence. In addition, the firm offers HeartRisk, a cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only tool supporting biopharmaceutical discovery and development. Its diagnostic solutions serve patients, healthcare providers, health systems, self-insured employers, and payors.

The company operates a laboratory facility designed for high-complexity testing in compliance with federal clinical laboratory standards. In addition to expanding its provider and channel partner relationships within the United States, it pursues international market opportunities, including commercial initiatives in India. Cardio Diagnostics Holdings is headquartered in Chicago, Illinois.

Summary of the business section of Cardio Diagnostics's latest annual report, written by StockData.

Company profile

Company

Legal name
Cardio Diagnostics Holdings, Inc.
Headquarters
Chicago, IL
Address
311 W. Superior Street, Suite 444 60645
Phone
(855) 226-9991
Employees
7, Dec 31, 2023
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Prager Metis CPAs, LLC, Hackensack, New Jersey

Stock & identifiers

Ticker
CDIO
Other tickers
CDIOW
Exchange
Nasdaq
IPO date
Nov 24, 2021
Shares outstanding
3M, Aug 7, 2026
Public float
$5.80M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-30 reverse, May 15, 2025; 1-for-30 reverse, May 13, 2025
SEC CIK
1870144
CUSIP
14159C202
ISIN
US14159C2026
LEI
529900E3UWQ6LHYRCK14
EIN
87-0925574

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James IntraterDirector71,596
Peter K. FungDirector–
Wendy J. BettsDirector–
Paul Frederick BurtonDirector8,803

Employees

Headcount reported in annual reports

“As of April 1, 2024, we had seven full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 4, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 7, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 25, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 10, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 31, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 31, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 26, 2022DelistingNotice of delisting from exchange (Form 25)
Oct 26, 2022Name changeName changed from Mana Capital Acquisition Corp. to Cardio Diagnostics Holdings, Inc.
May 31, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 25, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 24, 2021IPOInitial public offering priced (424B4 prospectus)
Nov 22, 2021ListingRegistration of securities on an exchange (Form 8-A)